Business
Enable Injections Announces $30 Million Investment from Sanofi to Accelerate Manufacturing Capabilities
CINCINNATI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”) a healthcare innovation company developing and manufacturing the enFuse® On-Body Delivery System (OBDS), announced today that Sanofi is making a $30 million investment to accelerate Enable’s manufacturing build-out, strengthen its supply chain capabilities, and drive commercial growth. “This investment from one of our key partners shows support of the enFuse platform and our shared commitment to making large-volume
About this update from Sanofi Sa
[{"type":"image","alt":"Enable Injections, Inc.","displaySize":"","headline":null,"caption":"Enable Injections, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/20c9520846a627e3d7773b7b8691da55"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/iHRyHQ1_7K6BzzUFMS8dOw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/20c9520846a627e3d7773b7b8691da55","width":300,"height":100}},"lazy":false},{"type":"text","content":"CINCINNATI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”) a healthcare innovation company developing and manufacturing the enFuse® On-Body Delivery System (OBDS), announced today that Sanofi is making a $30 million investment to accelerate Enable’s manufacturing build-out, strengthen its supply chain capabilities, and drive commercial growth.","length":372,"tagName":"p"},{"type":"text","content":"“This investment from one of our key partners shows support of the enFuse platform and our shared commitment to making large-volume subcutaneous injectable therapies more convenient for patients, including oncology,” said Michael D. Hooven, Chairman and CEO of Enable Injections. “Expanding our manufacturing capabilities is key to meeting the needs of our partners while bringing innovative treatment options to patients, worldwide.”","length":434,"tagName":"p"},{"type":"text","content":"This funding will further strengthen Enable’s ability to meet growing demand for the enFuse system, which is designed to subcutaneously administer large-volume medicines beginning with the click of a button, featuring a small, hidden, and retractable needle.","length":258,"tagName":"p"},{"type":"text","content":"Enable’s enFuse hands-free on-body injector (OBI) was part of Sanofi’s Sarclisa IRAKLIA phase 3 study in newly diagnosed multiple myeloma (MM) and the IZALCO phase 2 study in relapsed or refractory MM, both presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2025. The OBI is an automated injector designed to subcutaneously administer the hyaluronidase-free subcutaneous formulation of Sarclisa. The use of the OBI for Sarclisa is currently under review by regulatory authorities.","length":514,"tagName":"p"},{"type":"text","content":"The closing of a Series B roun...